Essent Biologics Introduces Human Demineralized Bone Matrix (DBM) Bioink For 3D Bioprinting And Tissue Engineering Research Applications

CENTENNIAL, Colo., Sept. 21, 2021 - Essent Biologics™, a nonprofit biotechnology company, today announced the launch of its spectral demineralized bone matrix (DBM), first of its kind, human-derived DBM for 3D bioprinting and tissue engineering research applications. Essent Biologics will provide an osteoconductive DBM powder with osteoinductive potential derived from adult human cortical bone.

The company's DBM powder is specifically formulated for bone tissue engineering research, complex in vitro bone models for drug discovery and other regenerative medicine research applications for musculoskeletal tissue. The product is an acid-extracted organic matrix from human bone and retains much of the components native to bone, such as calcium-based solids, inorganic phosphates and some trace of cell debris.

"We are excited to launch our first scaffold product for the regenerative medicine space," said Corey Stone, President, Essent Biologics. "Our DBM will support research efforts for next generation bone therapeutics, produce validated utility, and demonstrate opportunities to enhance outcomes in bone repair."

DBM is a biomaterial used in bone defects with a long track record of clinical use in diverse forms. Essent Biologics' DBM for research use is the ideal particle size for extrusion 3D bioprinting at 125-355µ particle size, recovered and processed without the use of animal products and tested for sterility and residual moisture.

For additional information on the company's product pipeline, please visit essentbiologics.org/products/


Drug Discovery & Development Article: Essent Biologics hMSCs

Essent Biologics’ new hMSC (human mesenchymal stem/stromal cell) product line was recently featured in Drug Discovery & Development magazine

Essent Biologics adipose-derived mesenchymal stem cells (hMSCs)

AlloSource (Centennial, Colo.), a central U.S. provider of allograft providers, has founded a separate nonprofit known as Essent Biologics to provide human-derived biomaterials for research. Essent has recently launched a human mesenchymal stem cells (hMSCs) offering for a range of research applications.

“The mission for the nonprofit is to maximize that gift of donation,” said Derek Mathers, head of business development at Essent Biologics.

Read the full article here


Essent Biologics announces human mesenchymal stem cells for regenerative medicine, biopharmaceutical and cell therapy research

Centennial, Colo. — June 8, 2021 — Essent Biologics™, a nonprofit biotechnology company setting a new standard in human-derived biomaterials and comprehensive data for research, today announced the launch of its human mesenchymal stem cells (hMSCs) for regenerative medicine, biopharmaceutical and cell therapy research. Essent Biologics will provide highly-characterized, low-passaged hMSCs. Each vial will contain over one million cells at thaw and have a passage level of P0 or P1 to ensure potency.

The company’s hMSCs are the first commercial hMSC product that is recovered, expanded and cryopreserved without the use of antibiotics or animal products. Additionally, with each order of hMSCs, Essent Biologics can provide full donor information coupled with a source biopsy called the Essent Origin Sample™.

This is an important milestone in getting our products into the hands of brilliant researchers, said Corey Stone, Executive Director, Essent Biologics. Our stem cells are the ideal input to your experiment, whether you are developing cell-based therapies, spheroids, bioprinted constructs, microfluidic chips or complex in vitro models.

As a strategic venture from AlloSource, a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients, Essent Biologics’ hMSCs are produced under current Good Manufacturing Practices (cGMP). The company builds their hMSCs to align with International Society for Cell & Gene Therapy (ISCT) guidelines to ensure identity, function and sterility.

For additional information on the company’s product pipeline, please visit essentbiologics.org/products/.


About Essent Biologics

Essent Biologics is setting a new standard in human-derived biomaterials and comprehensive data for research. The nonprofit biotechnology company provides low-passaged primary cells, research tissue and scaffold materials to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. In order to ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.


CBSA Fireside Chat | Punctuate Cell Therapy Research with Essent Biologics

Our Executive Director, Corey Stone, was recently interviewed by CBSA to share how Essent Biologics is setting a new standard in human-derived biomaterials and biology data for research and contributing to Colorado’s rapidly growing life sciences community. Ethan Mann, Ph.D., MBA, Chief Executive Officer of Validus Cellular Therapeutics, Inc. led the discussion touching on a range of topics including human biomaterials, mesenchymal stem cell therapy, drug development, and more. Thank you to our sponsor AlloSource!


Essent Biologics featured in CompanyWeek Article

Executive Director Corey Stone sees a bright future supplying stem cells to regenerative medicine researchers
Photo Jonathan Castner

Following the launch of Essent Biologics, local Colorado manufacturing outlet, CompanyWeek, highlighted the business in a feature story. A new venture of AlloSource, Essent Biologics is on a mission to empower medical researchers.

"For the past decade, AlloSource has developed this core expertise and knowledge around deriving primary cells from deceased allogeneic donors," says Stone. "When I came to AlloSource [in 2017], I asked a very basic question: 'What are we doing with all these cells that come from our donors?' . . . There was a gap there. We had access to donors, and we weren't really utilizing that aspect of the donor in new markets." Such cells represent a valuable resource for R&D in regenerative medicine and a means to "honor the gift of donation in a different way," he adds. The 2021 launch of Essent Biologics is the culmination of that line of thought.

Read the full story here. 


Essent Biologics Company Overview Video: Punctuate Your Research

Essent Biologics™, a nonprofit biotechnology company emerging from two years of stealth-mode operation, announced its 2021 launch as a new venture to meet the growing need for human-derived biomaterials and data to the regenerative medicine research community.

 


Essent Biologics announces Derek Mathers as head of business development

Centennial, Colo. — February 16, 2021 — Essent Biologics™, a nonprofit biotechnology company providing low passaged primary cells, origin tissue, scaffolds and data to advance regenerative medicine research, today announced the appointment of Derek Mathers as Head of Business Development.

Prior to his role with Essent, Derek served as Director, Strategic Accounts for Advanced Solutions Life Sciences (ASLS), driving revenue through global 3D bioprinting partnerships with leading life science companies. Before ASLS, Derek led global sales at Worrell, where he consulted with leading healthcare companies to design, test and manufacture complex medical devices. While at Worrell, Derek also taught night classes as an adjunct professor of 3D Printing at the University of Minnesota (UMN).

“We are thrilled to welcome Derek to our team,” said Corey Stone, Executive Director, Essent Biologics. “His knowledge and expertise will help drive Essent’s growth, as we continue to set a new standard in the field of regenerative medicine.”

Derek earned his Bachelor of Science in Entrepreneurial Management and Digital Marketing from UMN’s Carlson School of Management and holds certificates in Tissue Engineering from Rice University, Cardiac Physiology and Anatomy from UMN, and Design for Additive Manufacturing from GE Additive.

“Essent has a unique opportunity to provide human-derived biomaterials for the next generation of regenerative therapies,” said Derek Mathers, Head of Business Development. “I am humbled and grateful to join this talented team and look forward to contributing to our mission.”


About Essent Biologics

Essent Biologics is setting a new standard in human-derived biomaterials and 3D biology data for research. The nonprofit biotechnology company provides low passaged primary cells, origin tissue and scaffolds, as well as comprehensive donor and product data to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. To ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.


Essent Biologics launches with a mission to provide human-derived biomaterials and 3D biology data for cell therapy and tissue engineering

Centennial, Colo. — January 26, 2021 — Essent Biologics™, a nonprofit biotechnology company emerging from two years of stealth-mode operation, today announced its launch as a new venture to meet the growing need for human-derived biomaterials and data to the regenerative medicine research community, as well as producing key inputs for further manufacturing by clinical partners.

As a new venture from AlloSource, one of the world’s leading manufacturers of fresh cartilage tissue used for joint repair and skin allografts to heal severe burns, Essent Biologics will leverage its connection to human tissue donation by providing low passaged primary cell lines, origin tissue and comprehensive donor data to advance translational research from benchtop to bedside. The company also has the capability to serve as a biomanufacturing partner, creating a large inventory of custom products.

“We are proud to set a new standard in human-derived biomaterials for research,” said Corey Stone, Executive Director, Essent Biologics. “Essent will motivate and empower the work researchers are doing by supporting the development of innovative therapies through quality biomaterials and powerful data.”

Essent Biologics will supply highly characterized human mesenchymal stem cells (MSCs) produced under current Good Manufacturing Practices (cGMP). The company has already partnered with leading academic research and biopharmaceutical companies who excitedly await Essent Biologics’ official product launch, anticipated in April. For additional information on the company’s product pipeline, please visit essentbiologics.org.

“The work Essent is doing to help accelerate research through human clinical trials is remarkable,” said Ethan Mann, CEO of Validus Cellular Therapeutics, Inc. “We are excited to partner with such an innovative company who will support research to develop new medical solutions, and we look forward to their future growth.”

According to Allied Market Research, the Cellular Therapy and Tissue Engineering industries are some of the fastest growing in the regenerative medicine sector. The Cellular Therapy market tallied a total expenditure of $7.25 billion in 2019 and is expected to hit $48.11 billion by 2027. The Tissue Engineering market tallied a total expenditure of $2.3 billion in 2019 and is expected to hit $6.8 billion by 2027. These strong growth rates are powered by an increase in clinical trials and manufacturing throughput.


About Essent Biologics

Essent Biologics is setting a new standard in human-derived biomaterials and 3D biology data for research. The nonprofit biotechnology company provides low passaged primary cells, origin tissue and scaffolds, as well as comprehensive donor and product data to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. To ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.